[1]
Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterology clinics of North America. 1990 Sep:19(3):683-712
[PubMed PMID: 1977703]
[2]
El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014 Jun:63(6):871-80. doi: 10.1136/gutjnl-2012-304269. Epub 2013 Jul 13
[PubMed PMID: 23853213]
Level 1 (high-level) evidence
[3]
Moayyedi P, Axon AT. Review article: gastro-oesophageal reflux disease--the extent of the problem. Alimentary pharmacology & therapeutics. 2005 Aug:22 Suppl 1():11-9
[PubMed PMID: 16042655]
[4]
Shaker R,Castell DO,Schoenfeld PS,Spechler SJ, Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association. The American journal of gastroenterology. 2003 Jul
[PubMed PMID: 12873567]
Level 3 (low-level) evidence
[5]
Eisen G. The epidemiology of gastroesophageal reflux disease: what we know and what we need to know. The American journal of gastroenterology. 2001 Aug:96(8 Suppl):S16-8
[PubMed PMID: 11510763]
[6]
Maton PN, Burton ME. Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use. Drugs. 1999 Jun:57(6):855-70
[PubMed PMID: 10400401]
[7]
Weberg R, Berstad K, Berstad A. Acute effects of antacids on gastric juice components in duodenal ulcer patients. European journal of clinical investigation. 1990 Oct:20(5):511-5
[PubMed PMID: 2124982]
[8]
Tarnawski A, Tanoue K, Santos AM, Sarfeh IJ. Cellular and molecular mechanisms of gastric ulcer healing. Is the quality of mucosal scar affected by treatment? Scandinavian journal of gastroenterology. Supplement. 1995:210():9-14
[PubMed PMID: 8578218]
Level 2 (mid-level) evidence
[9]
Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Annals of internal medicine. 1991 Feb 15:114(4):307-19
[PubMed PMID: 1987878]
[10]
Schucker JJ, Ward KE. Hyperphosphatemia and phosphate binders. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2005 Nov 15:62(22):2355-61
[PubMed PMID: 16278327]
[11]
Rodriguez-Stanley S, Ahmed T, Zubaidi S, Riley S, Akbarali HI, Mellow MH, Miner PB. Calcium carbonate antacids alter esophageal motility in heartburn sufferers. Digestive diseases and sciences. 2004 Nov-Dec:49(11-12):1862-7
[PubMed PMID: 15628717]
[12]
Tarnawski A, Hollander D, Gergely H. Antacids: new perspectives in cytoprotection. Scandinavian journal of gastroenterology. Supplement. 1990:174():9-14
[PubMed PMID: 2205902]
Level 3 (low-level) evidence
[13]
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2003 Oct:42(4 Suppl 3):S1-201
[PubMed PMID: 14520607]
Level 2 (mid-level) evidence
[14]
Chao HH, Guo CH, Huang CB, Chen PC, Li HC, Hsiung DY, Chou YK. Arsenic, cadmium, lead, and aluminium concentrations in human milk at early stages of lactation. Pediatrics and neonatology. 2014 Apr:55(2):127-34. doi: 10.1016/j.pedneo.2013.08.005. Epub 2013 Nov 11
[PubMed PMID: 24231114]
[15]
Fanni D, Ambu R, Gerosa C, Nemolato S, Iacovidou N, Van Eyken P, Fanos V, Zaffanello M, Faa G. Aluminum exposure and toxicity in neonates: a practical guide to halt aluminum overload in the prenatal and perinatal periods. World journal of pediatrics : WJP. 2014 May:10(2):101-7. doi: 10.1007/s12519-014-0477-x. Epub 2014 May 7
[PubMed PMID: 24801228]
[16]
Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul:131(1):278-82
[PubMed PMID: 16831610]
[17]
Tsou VM, Young RM, Hart MH, Vanderhoof JA. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics. 1991 Feb:87(2):148-51
[PubMed PMID: 1987526]
[18]
Woodard-Knight L, Fudge A, Teubner J, Simmer K. Aluminium absorption and antacid therapy in infancy. Journal of paediatrics and child health. 1992 Jun:28(3):257-9
[PubMed PMID: 1605980]
[19]
Sedman A. Aluminum toxicity in childhood. Pediatric nephrology (Berlin, Germany). 1992 Jul:6(4):383-93
[PubMed PMID: 1498007]
[20]
Robinson RF, Casavant MJ, Nahata MC, Mahan JD. Metabolic bone disease after chronic antacid administration in an infant. The Annals of pharmacotherapy. 2004 Feb:38(2):265-8
[PubMed PMID: 14742764]
[21]
Pivnick EK, Kerr NC, Kaufman RA, Jones DP, Chesney RW. Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clinical pediatrics. 1995 Feb:34(2):73-8
[PubMed PMID: 7729110]
[22]
Walden DM, Khotimchenko M, Hou H, Chakravarty K, Varshney J. Effects of Magnesium, Calcium, and Aluminum Chelation on Fluoroquinolone Absorption Rate and Bioavailability: A Computational Study. Pharmaceutics. 2021 Apr 21:13(5):. doi: 10.3390/pharmaceutics13050594. Epub 2021 Apr 21
[PubMed PMID: 33919271]
[23]
Khandeparkar A, Rataboli PV. A study of harmful drug-drug interactions due to polypharmacy in hospitalized patients in Goa Medical College. Perspectives in clinical research. 2017 Oct-Dec:8(4):180-186. doi: 10.4103/picr.PICR_132_16. Epub
[PubMed PMID: 29109936]
Level 3 (low-level) evidence